Forskningsområder

Publications

PhD dissertations

  1. Christensen, Anette Luther. Modelling gradually changing seasonal variation in hospitalisations with stroke in atrial fibrillation patients; Denmark, Aarhus University, 2012
  2. Rix, Thomas. Fish, marine n-3 polyunsaturated fatty acids, and the development of atrial fibrillation; Denmark, Aarhus University, 2013
  3. Gamst, Jacob. Atrial Fibrillation: Risk and Prognosis in Critical Illness; Denmark, Aarhus University, 2014
  4. Vadmann, Henrik. Thromboembolism and death in patients with atrial flutter, Aalborg University Hospital, 2016.
  5. Høgh, Vibeke. Living with Atrial Fibrillation: Exploring the context, complexity, and magnitude of the patient perspective. Aalborg University Hospital, 2016.
  6. Gu, Jiwei. Postoperative New-Onset Atrial Fibrillation Following Cardiac Surgery with Special reference to Potential New Predictors. Aalborg Univeristy, 2017
  7. Mortensen, Lotte Maxild. N-3 and n-6 polyunsaturated fatty acids: metabolic pathways, interaction and risk of atrial fibrillation. 2017 

Scientific reports

Lars Hvilsted Rasmussen, Erik C. L. Grove, Steen Elkjær Husted, Torben Bjerregaard Larsen, Jørgen Jespersen, Thomas Decker Christensen. Danish Society of Cardiology National Treatment Guidelines 2010. Chapter 15. Atrial fibrillation and Atrial flutter (thrombosis section). ISBN: ISBN-13: 978-87-92010-10-0.

 

Scientific broadcasts

JACC (to follow)

Torben Bjerregaard Larsen. The patient who is elderly, cognitively impaired and falling. Cardio Vascular TV 2014 (13:20-21:20) (http://quadia.webtvframework.com/medtalks/_app/player/?id=493954)

 

Articles – peer reviewed

2017

  1. EHRA Scientific Committee Task Force: Gorenek B, Pelliccia A, Benjamin EJ, Boriani G, Crijns HJ, Fogel RI, Van Gelder IC, Halle M, Kudaiberdieva G, Lane DA, Larsen TB, Lip GY, Løchen ML, Marín F, Niebauer J, Sanders P, Tokgozoglu L, Vos MA, Van Wagoner DR; Document reviewers:., Fauchier L, Savelieva I, Goette A, Agewall S, Chiang CE, Figueiredo M, Stiles M, Dickfeld T, Patton K, Piepoli M, Corra U, Marques-Vidal PM, Faggiano P, Schmid JP, Abreu A. European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society  (APHRS). Europace. 2017 Feb 1;19(2):190-225.
  2. Gu J, Andreasen JJ, Melgaard J, Lundbye-Christensen S, Hansen J, Schmidt EB, Thorsteinsson K, Graff C. Preoperative Electrocardiogram Score for Predicting New-Onset Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery. J Cardiothorac Vasc Anesth. 2017 Feb;31(1):69-76.
  3. Gu, Jiwei; Andreasen, Jan Jesper; Melgaard, Jacob; Lundbye-Christensen, Søren; Hansen, John; Schmidt, Erik Berg; Thorsteinsson, Kristinn; Graff, Claus. Preoperative Electrocardiogram Score for Predicting New-Onset Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery.  I: Journal of Cardiothoracic and Vascular Anesthesia, Vol. 31, Nr. 1, 2017, s. 69-76. Publikation: Forskning - peer review › Tidsskriftartikel
  4. Gu J, Skals RK, Torp-Pedersen C, Lundbye-Christensen S, Jakobsen CJ, Bæch J, Petersen MS, Andreasen JJ. Storage time of intraoperative transfused allogeneic red blood cells is not associated with new-onset postoperative atrial fibrillation in cardiac surgery. PLoS One. 2017 Feb 22;12(2):e0172726.
  5. Lane DA, Skjøth F, Lip GYH, Larsen TB, Kotecha D. Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care. J Am Heart Assoc. 2017 Apr 28;6(5).
  6. Mørk, Morten; Handberg, Aase; Pedersen, Shona; Jørgensen, Malene M; Bæk, Rikke; Nielsen, Morten K.; Kristensen, Søren R. Prospects and limitations of antibody-mediated clearing of lipoproteins from blood plasma prior to nanoparticle tracking analysis of extracellular vesicles.  I: Journal of Extracellular Vesicles, Vol. 6, Nr. 1, 1308779, 2017. Publikation: Forskning - peer review › Tidsskriftartikel
  7. Nielsen PB, Johnsen SP. Letter by Nielsen and Johnsen Regarding Article, "Optimal Timing of Anticoagulant Treatment After Intracerebral Hemorrhage in Patients With Atrial Fibrillation". Stroke. 2017 Apr;48(4):e115.
  8. Nielsen PB, Larsen TB, Skjøth F, Lip GY. Outcomes Associated With Resuming Warfarin Treatment After Hemorrhagic Stroke or Traumatic Intracranial Hemorrhage in Patients With Atrial Fibrillation. JAMA Intern Med. 2017 Apr 1;177(4):563-570
  9. Nielsen PB, Lip GY. Adding Rigor to Stroke Rate Investigations in Patients With Atrial Fibrillation. Circulation. 2017 Jan 17;135(3):220-223.
  10. Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GY, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017 Feb 10;356:j510.
  11. Overvad TF, Nielsen PB, Lip GY. Treatment thresholds for stroke prevention in atrial fibrillation: observations on the CHA2DS2-VASc score. Eur Heart J Cardiovasc Pharmacother. 2017 Jan;3(1):37-41

2016

  1. Boriani G, Laroche C, Diemberger I, Popescu MI, Rasmussen LH, Petrescu L, Crijns HJ, Tavazzi L, Maggioni AP, Lip GY. Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomes.Sci Rep. 2016;6:30271.
  2. Christensen TD, Grove EL, Nielsen PB, Larsen TB. Self-managed oral anticoagulant therapy: a call for implementation. Expert Rev Cardiovasc Ther. 2016 [Epub ahead of print]
  3. Dahm CC, Chomistek AK, Jakobsen MU, Mukamal KJ, Eliassen AH, Sesso HD, Overvad K, Willett WC, Rimm EB, Chiuve SE.  Adolescent Diet Quality and Cardiovascular Disease Risk Factors and Incident Cardiovascular Disease in Middle-Aged Women. J Am Heart Assoc. 2016 Dec 20;5(12).
  4. Deharo JC, Sciaraffia E, Leclercq C, Amara W, Doering M, Bongiorni MG, Chen J, Dagres N, Estner H, Larsen TB, Johansen JB, Potpara TS, Proclemer A, Pison L, Brunet C, Blomström-Lundqvist C; Perioperative management of antithrombotic treatment during implantation or revision of cardiac implantable electronic devices: the European Snapshot Survey on Procedural Routines for Electronic Device Implantation (ESS-PREDI)Coordinated by the Scientific Initiatives Committee of the European Heart Rhythm AssociationEuropace. 2016;18:778-84
  5. Dinesen PT, Schmidt EB. Marine n-3 fatty acids and the risk of new-onset postoperative atrial fibrillation after cardiac surgery. Vascul Pharmacol. 2016 Dec;87:23-25.
  6. Eide IA, Dahle DO, Svensson M, Hartmann A, Åsberg A, Bjerve KS, Christensen JH, Schmidt EB, Lauritsen ME, Lund K, Jenssen T. Plasma levels of marine n-3 fatty acids and cardiovascular risk markers in renal transplant recipients. Eur J Clin Nutr. 2016 [Epub ahead of print]
  7. Forouhi NG, Imamura F, Sharp SJ, Koulman A, Schulze MB, Zheng J, Ye Z, Sluijs I, Guevara M, Huerta JM, Kröger J, Wang LY, Summerhill K, Griffin JL, Feskens EJ, Affret A, Amiano P, Boeing H, Dow C, Fagherazzi G, Franks PW, Gonzalez C, Kaaks R, Key TJ, Khaw KT, Kühn T, Mortensen LM, Nilsson PM, Overvad K, Pala V, Palli D, Panico S, Quirós JR, Rodriguez-Barranco M, Rolandsson O, Sacerdote C, Scalbert A, Slimani N, Spijkerman AM, Tjonneland A, Tormo MJ, Tumino R, van der A DL, van der Schouw YT, Langenberg C, Riboli E, Wareham NJ.
    PLoS Med. 2016 Jul 19;13(7):e1002094. 
  8. Gorst-Rasmussen A, Lip GY, Bjerregaard Larsen T. Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care.Pharmacoepidemiol Drug Saf. 2016 [Epub ahead of print]
  9. Gu J, Lundbye-Christensen S, Eschen RB, Andreasen A, Andreasen JJ. Marine n-3 fatty acids are incorporated into atrial tissue but do not correlate with postoperative atrial fibrillation in cardiac surgery. Vascul Pharmacol. 2016 Dec;87:70-75.
  10. Helnæs A, Kyrø C, Andersen I, Lacoppidan S, Overvad K, Christensen J, Tjønneland A, Olsen A. Intake of whole grains is associated with lower risk of myocardial infarction: the Danish Diet, Cancer and Health Cohort. Am J Clin Nutr. 2016;103:999-1007
  11. Hernández Madrid A, Potpara TS, Dagres N, Chen J, Larsen TB, Estner H, Todd D, Bongiorni MG, Sciaraffia E, Proclemer A, Cheggour S, Amara W, Blomstrom-Lundqvist C. Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a self-assessment patient survey conducted by the European Heart Rhythm Association. Europace. 201618:463-67
  12. Hoegh V, Lundbye-Christensen S, Delmar C, Frederiksen K, Riahi S, Overvad K.  Association between the diagnosis of atrial fibrillation and aspects of health status: a Danish cross-sectional study.  Scand J Caring Sci. 2016 Sep;30(3):507-17. doi: 10.1111/scs.12272
  13. Larsen TB. Hæmostase og Antikoagulation – afsnit i bogen “Den akutte patient”.
  14. Larsen TB. Risk of venous thromboembolism in patients with heart failure. Lancet Haematol. 2016;3:e6-7
  15. Larsen TB, Lip GY, Gorst-Rasmussen A. Anticoagulant therapy after venous thromboembolism and 10-year mortality. Int J Cardiol. 2016 [Epub ahead of print]
  16. Lip GY, Nielsen PB. Should Patients with Atrial Fibrillation and 1 Stroke Risk Factor (CHA2DS2-VASc Score 1 in Men, 2 in Women) Be Anticoagulated? Yes: Even 1 Stroke Risk Factor Confers a Real Risk of Stroke. Circulation. 2016;133:1498-503
  17. Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study BMJ. 2016;353:i3189
  18. Melgaard L, Gorst-Rasmussen A, Søgaard P, Rasmussen LH, Lip GY, Larsen TB. Diabetes mellitus and risk of ischemic stroke in patients with heart failure and no atrial fibrillation. Int J Cardiol. 2016. Int J Cardiol. 2016; 209:1-6
  19. Melgaard L, Gorst-Rasmussen A, Rasmussen LH, Lip GY, Larsen TB. Vascular Disease and Risk Stratification for Ischemic Stroke and All-Cause Death in Heart Failure Patients without Diagnosed Atrial Fibrillation: A Nationwide Cohort Study. PLoS One. 2016;11:e015226
  20. Monrad M, Sajadieh A, Christensen JS, Ketzel M, Raaschou-Nielsen O, Tjønneland A, Overvad K, Loft S, Sørensen M. Residential exposure to traffic noise and risk of incident atrial fibrillation: A cohort study. Environ Int. 2016;92-93:457-463
  21. Mostofsky E, Johansen MB, Lundbye-Christensen S, Tjønneland A, Mittleman MA, Overvad K.  Risk of atrial fibrillation associated with coffee intake: Findings from the Danish Diet, Cancer, and Health study.  Eur J Prev Cardiol. 2016 Jun;23(9):922-30.
  22. Mørk, Morten; Pedersen, Shona; Botha, Jaco; Lund, Sigrid Marie; Kristensen, Søren Risom. Preanalytical, analytical, and biological variation of blood plasma submicron particle levels measured with nanoparticle tracking analysis and tunable resistive pulse sensing. I: Scandinavian Journal of Clinical & Laboratory Investigation, Vol. 76, Nr. 5, 2016, s. 349-360.Publikation: Forskning - peer review › Tidsskriftartike
  23. Nielsen PB. Pharmacoepidemiological comparisons between acenocoumarol and dabigatran: interpretation of data reflecting clinical practice. Europace. 2016 [Epub ahead of print]
  24. Nielsen P B, Christensen T D, Larsen TB. The use of point of care coagulometers in clinical trials (response to the Editor). BMJ 2016;352:i575 - http://www.bmj.com/content/352/bmj.i575/rr-3
  25. Nielsen PB, Larsen TB, Gorst-Rasmussen A, Skjøth F, Lip GY. β-Blockers in Atrial Fibrillation Patients With or Without Heart Failure: Association With Mortality in a Nationwide Cohort Study. Circ Heart Fail. 2016;9(2):e002597.
  26. Nielsen PB, Larsen TB, Lip GY. Letter by Nielsen et al Regarding Article, "Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA2DS2-VASc Score of 1: Systematic Review and Meta-Analysis". Stroke. 2016;47(7):e193.
  27. Nielsen PB, Larsen TB, Lip GY. Misconceptions on Interpretation of Risk Prediction Tools in Atrial Fibrillation. Am J Med. 2016;129:e31
  28. Nielsen PB, Larsen TB, Lip GY. Recalibration of the HAS-BLED score - should haemorrhagic stroke account for 1 or 2 points? Chest. 2016. Chest. 2016; 149:311-14
  29. Nielsen PB, Skjøth F. A two-sided evaluation of benefit and harm from antithrombotic treatment in atrial fibrillation: Balancing clinical application and statistical methodology. Thromb Haemost. 2016;116(3):405-6.
  30. Overvad TF, Brønnum Nielsen P, Bjerregaard Larsen T. Recent Diabetes and Atrial Fibrillation Report Diverges From Pre-Existing Evidence. J Am Coll Cardiol. 2016;67:2318-19
  31. Potpara TS, Jokic V, Dagres N, Larsen TB, Lane DA, Hindricks G, Lip GY. Non-vitamin K oral anticoagulant drugs for stroke prevention in patients with atrial fibrillation and chronic kidney disease. Curr Med Chem. 2016;23(19):2055-2069
  32. Vadmann H, Gorst-Rasmussen A, Hjortshøj SP, Riahi S, Lip GY, Larsen TB. Death and thrombo-embolic risk after ablation of atrial flutter compared with atrial fibrillation: a nationwide cohort study. Europace. 2016 [Epub ahead of print]
  33. Vestergaard AS, Skjøth F, Lip GY, Larsen TB. Effect of Anticoagulation on Hospitalization Costs After Intracranial Hemorrhage in Atrial Fibrillation: A Registry Study. Stroke. 2016;47:979-85

2015

  1. Albertsen IE, Overvad TF, Lip GY, Larsen TB. Smoking, atrial fibrillation, and ischemic stroke: a confluence of epidemics. Curr Opin Cardiol. 2015;30:512-17
  2. Amara W, Larsen TB, Sciaraffia E, Hernández Madrid A, Chen J, Estner H, Todd D, Bongiorni MG, Potpara TS, Dagres N, Sagnol P, Blomstrom-Lundqvist C. Patients' attitude and knowledge about oral anticoagulation therapy: results of a self-assessment survey in patients with atrial fibrillation conducted by the European Heart Rhythm Association. Europace. 2015 [Epub ahead of print]
  3. Blann AD, Skjøth F, Rasmussen LH, Larsen TB, Lip GY. Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb Haemost. 2015;114:403-9
  4. Chen J, Hocini M, Larsen TB, Proclemer A, Sciaraffia E, Blomström-Lundqvist C; Scientific Initiative Committee, European Heart Rhythm Association. Clinical management of arrhythmias in elderly patients: results of the European Heart Rhythm Association survey. Europace. 2015;17:314-7
  5. Delmar H, Frederiksen K, Høgh V. Livskvalitet hos patienter, der lever med atrieflimren – et komplekst begreb. BestPractice 2015;13:18-19
  6. Dagres N, Bongiorni MG, Larsen TB, Hernandez-Madrid A, Pison L, Blomström-Lundqvist C; Conducted by the Scientific Initiatives Committee, European Heart Rhythm Association Current ablation techniques for persistent atrial fibrillation: results of the European Heart Rhythm Association Survey. Europace. 2015;17:1596-600
  7. Fumagalli M, Moltke I, Grarup N, Racimo F, Bjerregaard P, Jørgensen ME, Korneliussen TS, Gerbault P, Skotte L, Linneberg A, Christensen C, Brandslund I, Jørgensen T, Huerta-Sánchez E, Schmidt EB, Pedersen O, Hansen T, Albrechtsen A, Nielsen R. Greenlandic Inuit show genetic signatures of diet and climate adaptation. Science. 2015;349:1343-47
  8. Gamst J, Christiansen CF, Rasmussen BS, Rasmussen LH, Thomsen RW. Pre-existing atrial fibrillation and risk of arterial thromboembolism and death in intensive care unit patients: a population-based cohort study. Crit Care. 2015;19:299
  9. Gorst-Rasmussen A, Skjøth F, Larsen TB, Rasmussen LH, Lip GY, Lane DA. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost. 2015 J Thromb Haemost 2015;13:495-504
  10. Hansen CP, Heitmann BL, Sørensen TI, Overvad K, Jakobsen MU. Intake of ruminant trans-fatty acids, assessed by diet history interview, and changes in measured body size, shape and composition. Public Health Nutr. 2015 [Epub ahead of print 
  11. Hoegh V, Lundbye-Christensen S, Delmar C, Frederiksen K, Riahi S, Overvad K. Association between the diagnosis of atrial fibrillation and aspects of health status: a Danish cross-sectional study. Scand J Caring Sci. 2015 [Epub ahead of print]
  12. Jakobsen MU, Madsen L, Dethlefsen C, Due KM, Halkjær J, Sørensen TI, Kristiansen K, Overvad K. Dietary n-6 PUFA, carbohydrate:protein ratio and change in body weight and waist circumference: a follow-up study. Public Health Nutr 2015;18:1317-23 
  13. Larsen TB. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients. Europace 2015;17:169-70
  14. Larsen TB, Potpara T, Dagres N, Proclemer A, Sciarrafia E, Blomström-Lundqvist C; Scientific Initiative Committee European Heart Rhythm Association. Preference for oral anticoagulation therapy for patients with atrial fibrillation in Europe in different clinical situations: results of the European Heart Rhythm Association Survey. Europace. 2015;17:819-24
  15. Lip GY, Laroche C, Boriani G, Cimaglia P, Dan GA, Santini M, Kalarus Z, Rasmussen LH, Popescu MI, Tica O, Hellum CF, Mortensen B, Tavazzi L, Maggioni AP. Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. Europace 2015;17:24-31
  16. Lip GY, Laroche C, Boriani G, Dan GA, Santini M, Kalarus Z, Rasmussen LH, Oliveira MM, Mairesse G, Crijns HJ, Simantirakis E, Atar D, Maggioni AP, Tavazzi L. Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2015;17:194-206
  17. Lip GY, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan GA, Kalarus Z, Crijns HJ, Oliveira MM, Tavazzi L, Maggioni AP, Boriani G. Heart failure in patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Pilot survey on Atrial Fibrillation. Eur J Heart Fail. 2015:17:570-82 
  18. Lip GY, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan GA, Kalarus Z, Crijns HJ, Oliveira MM, Tavazzi L, Maggioni AP, Boriani G. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. Europace. 2015 [Epub ahead of print]
  19. Lip GY, Nielsen PB, Skjøth F, Rasmussen LH, Larsen TB. Atrial fibrillation patients categorized as "not for anticoagulation" according to the 2014 Canadian cardiovascular society algorithm are not "low risk". Can J Cardiol 2015; 31: 24-8
  20. Lip GY, Skjøth F, Rasmussen LH, Larsen TB. Oral Anticoagulation, Aspirin, or No Therapy in Patients With Nonvalvular AF With 0 or 1 Stroke Risk Factor Based on the CHA2DS2-VASc Score. J Am Coll Cardiol. 2015 2015;65:1385-94 [Epub ahead of print]
  21. Lip GY, Skjøth F, Nielsen PB, Larsen TB. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. Thromb Haemost. 2015;114:826-34
  22. Lip GY, Skjøth F, Rasmussen LH, Nielsen PB, Larsen TB. Net Clinical Benefit for Oral Anticoagulation, Aspirin, or No Therapy in Nonvalvular Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex). J Am Coll Cardiol. 2015;66:488-90
  23. Madzak A, Larsen TB, Lane DA, Lip GY, Nielsen PB. Composite end point analyses of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation. Expert Rev Cardiovasc Ther. 2015;13:1155-63
  24. Marcucci M, Skjøth F, Lip GY, Iorio A, Larsen TB. A decisional model to individualize warfarin recommendations: Expected impact on treatment and outcome rates in a real-world population with atrial fibrillation. Int J Cardiol. 2015;203:785-90
  25. Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GY. Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation. JAMA. 2015;314:1030-1038
  26. Mostofsky E, Johansen MB, Lundbye-Christensen S, Tjønneland A, Mittleman MA, Overvad K. Risk of atrial fibrillation associated with coffee intake: Findings from the Danish Diet, Cancer, and Health study. Eur J Prev Cardiol. 2015 [Epub ahead of print]
  27. Munkholm, SB, Jakobsen, C-J, Mortensen, PE, Lundbye-Christensen, S & Andreasen, JJ 2015, 'Validation of post-operative atrial fibrillation in the Western Denmark Heart Registry' Danish Medical Journal, vol 62, nr. 12, A5162.
  28. Nielsen PB, Chao TF. The risks of risk scores for stroke risk assessment in atrial fibrillation. Thromb Haemost. 2015;113:1170-3
  29. Nielsen PB, Larsen TB, Gorst-Rasmussen A, Skjøth F, Rasmussen LH, Lip GY. Intracranial haemorrhage and subsequent ischemic stroke in patients with atrial fibrillation: A nationwide cohort study. Chest. 2015 Jun;147(6):1651-8.
  30. Nielsen PB, Larsen TB, Skjøth F, Gorst-Rasmussen A, Rasmussen LH, Lip GY. Restarting Anticoagulant Treatment After Intracranial Haemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality and Bleeding: A Nationwide Cohort Study. Circulation. 2015;132:517-25
  31. Nielsen PB, Larsen TB, Lip GY. Recalibration of the HAS-BLED score - should haemorrhagic stroke account for 1 or 2 points? Chest. 2015 [Epub ahead of print]
  32. Nielsen PB, Skjøth F, Rasmussen LH, Larsen TB, Lip GY. Using the CHA2DS2-VASc Score for Stroke Prevention in Atrial Fibrillation: A Focus on Vascular Disease, Women, and Simple Practical Application. Can J Cardiol. 2015;31:820.e9-10
  33. Overvad TF, Nielsen PB, Larsen TB. Underbehandling kontra overbehandling af patienter med atrieflimren. Ugeskr Læger 2015;177:1652-53
  34. Overvad TF, Nielsen PB, Larsen TB. Comparison of Atrial Fibrillation Guidelines. J Gen Intern Med. 2015;30:1404
  35. Overvad TF, Skjøth F, Lip GY, Lane DA, Albertsen IE, Rasmussen LH, Larsen TB. Duration of Diabetes Mellitus and Risk of Thromboembolism and Bleeding in Atrial Fibrillation: Nationwide Cohort Study. Stroke. 2015;46:2168-74
  36. Petersen KE1, Johnsen NF1, Olsen A1, Albieri V1, Olsen LK1, Dragsted LO, Overvad K, Tjønneland A1, Egeberg R1. The combined impact of adherence to five lifestyle factors on all-cause, cancer and cardiovascular mortality: a prospective cohort study among Danish men and women. Br J Nutr. 2015 [Epub ahead of print]
  37. Pison L, Potpara TS, Chen J, Larsen TB, Bongiorni MG, Blomström-Lundqvist C; Conducted by the Scientific Initiative Committee, European Heart Rhythm Association. Left atrial appendage closure-indications, techniques, and outcomes: results of the European Heart Rhythm Association Survey. Europace. 2015;17:642-6
  38. Potpara TS, Larsen TB, Deharo JC, Rossvoll O, Dagres N, Todd D, Pison L, Proclemer A, Purefellner H, Blomström-Lundqvist C; Conducted by the Scientific Initiatives Committee of the European Heart Rhythm Association (EHRA) . Oral anticoagulant therapy for stroke prevention in patients with atrial fibrillation undergoing ablation: results from the First European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA). Europace. 2015;17:986-993
  39. Potpara TS, Lenarczyk R, Larsen TB, Deharo JC, Chen J, Dagres N; Conducted by the Scientific Initiatives Committee, European Heart Rhythm Association; Conducted by the Scientific Initiatives Committee European Heart Rhythm Association. Management of atrial fibrillation in patients with chronic kidney disease in Europe Results of the European Heart Rhythm Association Survey
    Europace. 2015;17:1862-7
  40. Potpara TS1, Pison L2, Larsen TB, Estner H4, Madrid A5, Blomström-Lundqvist C6; Conducted by the Scientific Initiatives Committee, and European Heart Rhythm Association; Conducted by the Scientific Initiatives Committee and European Heart Rhythm Association. How are patients with atrial fibrillation approached and informed about their risk profile and available therapies in Europe? Results of the European Heart Rhythm Association Survey. Europace. 2015;17:468-72
  41. Riahi S, Arbelo E, Brugada J, Maggioni AP, Tavazzi L, Vardas P, Laroche C, Efremidis M, Xhaet O, Woźniak A, Van Gelder IC, Hjortshoj S. Regional differences in referral, procedures, and outcome after ablation for atrial fibrillation in Europe: a report from the Atrial Fibrillation Ablation Pilot Registry of the European Society of Cardiology. Europace. 2015 [Epub ahead of print]
  42. Roswall N, Høgh V, Envold-Bidstrup P, Raaschou-Nielsen O, Ketzel M, Overvad K, Olsen A, Sørensen M. Residential Exposure to Traffic Noise and Health-Related Quality of Life-A Population-Based StudyPLoS One 2015;10:e0120199
  43. Vadmann H, Nielsen PB, Hjortshoj SP, Riahi S, Rasmussen LH, Lip GYH, Larsen TB. Atrial flutter and thromboembolic risk: a systematic review. Heart 2015;101:1446-55
  44. Vadmann H, Pedersen SS, Nielsen JC, Rodrigo-Domingo M, Pehrson S, Johannessen A, Hansen PS, Johansen JB, Riahi S. Attitudes Towards Catheter Ablation for Atrial Fibrillation: A Nationwide Survey Among Danish Cardiologists. Pacing Clin Electrophysiol. 2015;38:1166-72

2014

  1. Albertsen IE, et al. (Rasmussen LH, Overvad K). The impact of smoking on thromboembolism and mortality in patients with incident atrial fibrillation: insights from the Danish Diet, Cancer and Health study. Chest 2014;145:559-66
  2. Ankarfeldt MZ, Angquist L, Jakobsen MU, Overvad K, Tjønneland A, Halkjaer J, Astrup A, Sørensen TI. Interactions of dietary protein and adiposity measures in relation to subsequent changes in body weight and waist circumference. Obesity 2014;2097-103
  3. Arbelo E, Brugada J, Hindricks G, Maggioni AP, Tavazzi L, Vardas P, Laroche C, Anselme F, Inama G, Jais P, Kalarus Z, Kautzner J, Lewalter T, Mairesse GH, Perez-Villacastin J, Riahi S, Taborsky M, Theodorakis G, Trines SA; on behalf of the Atrial Fibrillation Ablation Pilot Study Investigators: a European Survey on Methodology and Results of Catheter Ablation for Atrial Fibrillation: conducted by the European Heart Rhythm Association. Eur Heart J 2014;35:1466-78
  4. Chen J, Todd DM, Hocini M, Larsen TB, Bongiorni MG, Blomström-Lundqvist C; Conducted by the Scientific Initiative Committee, European Heart Rhythm Association, Current periprocedural management of ablation for atrial fibrillation in Europe: results of the European Heart Rhythm Association survey.
  6. 2014;16:378-81
  7. Dalsgaard AB, Jakobsen CS, Riahi S, Hjortshøj S. Groin hematoma after electrophysiological procedures - incidence and predisposing factors. Scand Cardiovasc J 2014;48:311-16
  8. Efimova E, Riahi S, Fiedler L, Esato M, Sommer P, Richter S, Breithardt O, Rolf S, Bollmann A, Hindricks G, Arya A. Adenosine sensitivity of retrograde fast pathway conduction in patients with slow-fast atrioventricular nodal reentrant tachycardia: A prospective study: Fast pathway's adenosine resistance. Heart Rhythm 2014;11:871-76
  9. Ferrari P, Licaj I, Muller DC, Kragh Andersen P, Johansson M, Boeing H, Weiderpass E, Dossus L, Dartois L, Fagherazzi G, Bradbury KE, Khaw KT, Wareham N, Duell EJ, Barricarte A, Molina-Montes E, Sanchez CN, Arriola L, Wallström P, Tjønneland A, Olsen A, Trichopoulou A, Benetou V, Trichopoulos D, Tumino R, Agnoli C, Sacerdote C, Palli D, Li K, Kaaks R, Peeters P, Beulens JW, Nunes L, Gunter M, Norat T, Overvad K, Brennan P, Riboli E, Romieu I. Lifetime alcohol use and overall and cause-specific mortality in the European Prospective Investigation into Cancer and nutrition (EPIC) study. BMJ Open 2014;4:e005245
  10. Frost L, Benjamin EJ, Fenger-Grøn M, Pedersen A, Tjønneland A, Overvad K.  Body fat, body fat distribution, lean body mass and atrial fibrillation and flutter. A danish cohort study. Obesity (Silver Spring) 2014;22:1546-52
  11. Gamst J, Christiansen CF, Rasmussen BS, Rasmussen LH, Thomsen RW. Pre-existing atrial fibrillation and risk of arterial thromboembolism and death following pneumonia: a population-based cohort study. BMJ Open 2014;4:e006486
  12. Husted S, De Caterina R, Andreotti F, Arnesen H, Bachmann F, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Storey RF, Weitz JI, Esc Working Group On Thrombosis Task Force On Anticoagulants In Heart Disease OB. Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost 2014;111:781-82
  13. Høgh V, Delmar C, Riahi S, Frederiksen K, Quality of Life – Exemplified through Patients Living with Atrial Fibrillation, J Nurs Care. 2014;3:1000150 (http://omicsgroup.org/journals/quality-of-life-exemplified-through-patients-living-with-atrial-fibrillation-2167-1168-3-150.pdf)
  14. Ankarfeldt MZ, Larsen SC1, Angquist L, Ahluwalia TS, Skaaby T, Roswall N, Tjønneland A, Halkjær J, Overvad K, Pedersen O, Hansen T, Linneberg A, Husemoen LL, Toft U, Heitmann BL, Sørensen TI, Interaction between genetic predisposition to obesity and dietary calcium in relation to subsequent change in body weight and waist circumference. Am J Clin Nutr 2014;99:957-65
  15. Larsen TB, Gorst-Rasmussen A, Rasmussen LH, Skjøth F, Rosenzweig M, Lip GY. Bleeding Events among New Starters and Switchers to Dabigatran Compared with Warfarin: an Observational Study among Patients with Atrial Fibrillation. Am J Med 2014;127:650-56
  16. Larsen TB, Nielsen PB, Skjøth F, Rasmussen LH, Lip GY. Non-vitamin k antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes. PLoS One 2014;9:e114445
  17. Larsen TB, Potpara T, Dagres N, Pison L, Estner H, Blomström-Lundqvist C; Scientific Initiative Committee, European Heart Rhythm Association, Stroke and bleeding risk evaluation in atrial fibrillation: results of the European Heart Rhythm Association survey, Europace 2014;16:698-702
  18. Larsen TB, Rasmussen LH, Gorst-Rasmussen A, Skjøth F, Lane DA, Lip GY. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: A nationwide cohort study. Am J Med 2014;127:1172-78
  19. Larsen TB, Rasmussen LH, Gorst-Rasmussen A, Skjøth F, Rosenzweig M, Lane DA, Lip GY. Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin: A nationwide cohort study. Am J Med 2014;127:329-36
  20. Larsen TB, Rasmussen LH, Gorst-Rasmussen A, Skjøth F, Rosenzweig M, Lane DA, Lip GY. The reply (Vedr.: Myocardial Ischemic Events in ‘Real World’ Patients with Atrial Fibrillation Treated with Dabigatran or Warfarin). Am J Med 2014;127:e21
  21. Larsen TB, Lip GY. Warfarin or novel oral anticoagulants for atrial fibrillation? Lancet 2014; 383:931-33
  22. Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH, Oliveira MM, Mairesse G, Crijns HJ, Simantirakis E, Atar D, Kirchhof P, Vardas P, Tavazzi L, Maggioni AP. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2014;16:308-19
  23. Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH, Ioachim PM, Tica O, Boriani G, Cimaglia P, Diemberger I, Hellum CF, Mortensen B, Maggioni AP. 'Real-world' antithrombotic treatment in atrial fibrillation: the EURObservational Research Programme Atrial Fibrillation General Pilot survey. Am J Med 2014;650-656
  24. Lip GY, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L, Petrescu L, Darabantiu D, Crijns HJ, Kirchhof P, Vardas P, Tavazzi L, Maggioni AP, Boriani G. Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry).
  26. 2014;35:3365-76
  27. Lip GY, Nielsen PB, Skjøth F, Lane DA, Rasmussen LH, Larsen TB. The value of the ESC guidelines for refining stroke risk stratification in patients with atrial fibrillation categorised as 'low risk' using the ATRIA stroke score: a nationwide cohort study. Chest 2014;146:1337-46
  28. Melgaard L, Rasmussen LH, Skjøth F, Lip GY, Larsen TB. Age Dependence of Risk Factors for Stroke and Death in Young Patients With Atrial Fibrillation: A Nationwide Study. Stroke 2014;45:1331-37
  29. Nielsen PB, Lane DA, Rasmussen LH, Lip GY, Larsen TB. Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clin Res Cardiol 2014 2015 May;104(5):418-2
  30. Nielsen PB, Lundbye-Christensen S, Hvilsted Rasmussen L, Larsen TB . Improvement of anticoagulant treatment using a dynamic decision support algorithm. Thrombosis Research 2014;133:375-379.
  31. Nilsson H1 Grove EL, Larsen TB, Nielsen PB, Skjøth F, Maegaard M, Christensen TD. Sex differences in treatment quality of self-managed oral anticoagulant therapy: 6,900 patient-years of follow-up. PLoS One 2014;9:e113627
  32. Oddershede L, Riahi S, Nielsen JC, Hjortshøj S, Andersen HR, Ehlers L. Health economic evaluation of single-lead atrial pacing vs. dual-chamber pacing in sick sinus syndrome. Europace. 2014;16:866-72
  33. Overvad TF, Rasmussen LH, Skjøth F, Overvad K, Albertsen IE, Lane DA, Lip GY, Larsen TB. Female sex as a risk factor for thromboembolism and death in patients with incident atrial fibrillation. The prospective Danish Diet, Cancer and Health study. Thromb Haemost 2014;112:789-95
  34. Potpara TS, Lip GY, Dagres N, Estner HL, Larsen TB, Blomström-Lundqvist C. Management of acute coronary syndrome in patients with non-valvular atrial fibrillation: results of the European Heart Rhythm Association Survey; Conducted by the Scientific Initiatives Committee, European Heart Rhythm Association. Europace 2014;16:293-8
  35. Pottegård A, Christensen RD, Wang SV, Gagne JJ, Larsen TB, Hallas, Pharmacoepidemiological assessment of drug interactions with vitamin K antagonists. J Pharmacoepidemiol Drug Saf 2014;23:1160-67
  36. Riber LP, Larsen TB, Christensen TD. Postoperative Atrial Fibrillation Prophylaxis After Lung Surgery: Systematic Review and Meta-Analysis. Ann Thorac Surg 2014;98:1989-97
  37. Rix TA, Joensen AM, Riahi S, Lundbye-Christensen S, Tjønneland A, Schmidt EB, Overvad K. A U-shaped association between consumption of marine n-3 fatty acids and development of atrial fibrillation/atrial flutter--a Danish cohort study. Europace 2014;16:1554-61
  38. Skjøth F, Larsen TB, Rasmussen LH, Lip GY. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb Haemost 2014;111:981-82
  39. Task Force Members, Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, Haeusler KG, Boriani G, Capodanno D, Gilard M, Zeymer U, Lane D; Document Reviewers, Storey RF, Bueno H, Collet JP, Fauchier L, Halvorsen S, Lettino M, Morais J, Mueller C, Potpara TS, Rasmussen LH, Rubboli A, Tamargo J, Valgimigli M, Zamorano JL. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014;35:3155-79
  40. Vadmann H, Grønlund J, Andreasen JJ. Torakoskopisk behandling af atrieflimren kan være et alternativ til perkutan radiofrekvensablation [Surgical thoracoscopic treatment of atrial fibrillation as an alternative to percutaneous radio frequency ablation]. Ugeskr. Læger 2014;22:2072-75
  41. Wagstaff AJ, Overvad TF, Lip GY, Lane DA. Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. QJM 2014;107:955-67

2013

  1. Albertsen IE, et al. (Rasmussen LH). Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis. Stroke. 2013;44:1329-36
  2. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013;109:569-79
  3. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI. Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013;109:569-79
  4. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI. Vitamin K antagonists in heart disease: Current status and perspectives (Section III). Position Paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013;110:1087-107
  5. Frost L, Benjamin EJ, Fenger-Grøn M, Pedersen A, Tjønneland A , Overvad K. Body fat, body fat distribution, lean body mass and atrial fibrillation: a Danish cohort study. Eur J Epidemiol 2013;28(Suppl 1):S79
  6. Jóanersarson J, Riahi S, Hjortshøj S. Kardiovertering af atrieflimren. Ugeskr Læger 2013;175:2549-2555
  7. Kasmeridis C, Apostolakis S, Ehlers L, Rasmussen LH, Boriani G, Lip GY. Cost Effectiveness of Treatments for Stroke Prevention in Atrial Fibrillation: Focus on the Novel Oral Anticoagulants.  Pharmacoeconomics 2013;31:971-80
  8. Larsen TB, Rasmussen LH, Skjøth F, Due KM, Callréus T, Rosenzweig M, Lip GY. Efficacy and safety of dabigatran etexilate and warfarin in 'real world' patients with atrial fibrillation: A prospective nationwide cohort study. J Am Coll Cardiol 2013; 61:2264-73
  9. Lip GY, Larsen TB, Skjøth F, Rasmussen LH. Reply. J Am Coll Cardiol. 2013;61:596
  10. Nielsen PB, Lundbye-Christensen S, Larsen TB, Kristensen SR, Hejlesen OK. Monitoring of anticoagulant therapy applying a dynamic statistical model. Comput Methods Programs Biomed. 2013:110:380-88
  11. Overvad TF, Rasmussen LH, Skjøth F, Overvad K, Lip GY, Larsen TB. Body mass index and adverse events in patients with incident atrial fibrillation. Am J Med 2013;126:640.e9-640.e17
  12. Overvad TF, Rasmussen LH, Skjøth F, Overvad K, Albertsen IE, Lane DA, Lip GY, Larsen TB. Alcohol intake and prognosis of atrial fibrillation. Heart 2013;99:1093-9.
  13. Overvad TF, Larsen TB, Albertsen IE, Rasmussen LH, Lip GY. Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation. Expert Rev Cardiovasc Ther 2013;11:1619-29
  14. Rix TA, Joensen AM, Riahi S, Lundbye-Christensen S, Overvad K, Schmidt EB. Marine n-3 fatty acids in adipose tissue and development of atrial fibrillation: a Danish cohort study. Heart 2013;99:1519-24
  15. Rix TA, Christensen JH, Schmidt EB. Omega-3 fatty acids and cardiac arrhythmias. Curr Opin Clin Nutr Metab Care 2013;16:168-73.
  16. Vadmann H, Gerdes C, Pehrson S, Hansen PS, Johannesen A, Djurhuus S, Riahi S. Radiofrekvensablation af atrieflimren [Radio frequency ablation of atrial fibrillation]. Ugeskr Læger 2013;175:2553-57

 

2012

  1. Christensen AL, Lundbye-Christensen S, Overvad K, Rasmussen LH, Dethlefsen C. Modeling gradually changing seasonal variation in count data using state space models: a cohort study of hospitalization rates of stroke in atrial fibrillation patients in Denmark from 1977 to 2011. BMC Med Res Methodol  2012;12, 174
  2. Christensen AL, Rasmussen LH, Baker MG, Lip GYP, Dethlefsen C, Larsen TB. Seasonality, incidence and prognosis in atrial fibrillation and stroke in Denmark and New Zealand. BMJ Open. 2012;2: e001210
  3. De Caterina R, Husted S, Wallentin L, Rasmussen LH et al. New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes, ESC Working Group on Thrombosis — Task Force on Anticoagulants in Heart Disease; Position Paper. J Am Coll Cardiol. 2012;59:1413-25
  4. Larsen TB, Lip GY, Skjøth F, Due KM, Overvad K, Rasmussen LH. The added predictive ability of the CHA2DS2VASc risk score for stroke and death in patients with atrial fibrillation: The prospective Danish Diet, Cancer and Health cohort study. Circ Cardiovasc Qual Outcomes 2012;5:335-42
  5. Lip GY, Larsen TB, Skjøth F, Rasmussen LH: Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. JACC 2012;607:38-46
  6. Lip GY, Ponikowski P, Andreotti F, Anker SD, Filippatos G, Homma S, Morais J, Pullicino P, Rasmussen LH et al. Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Eur J Heart Fail 2012;14:681-95
  7. Rix TA, Riahi S, Overvad K, Lundbye-Christensen S, Schmidt EB, Joensen AM. Validity of the diagnoses atrial fibrillation and atrial flutter in a Danish patient registry. Scand Cardiovasc J 2012;46:149-53
  8. Rix TA, Mortensen LM, Schmidt EB. Fish, marine n−3 fatty acids, and atrial fibrillation – experimental data and clinical effects. Front. Physiol 2012;3:152

2011

  1. Christensen AL, Lundbye-Christensen S, Dethlefsen C. Poisson regression models outperform the geometrical model in estimating the peak-to-trough ratio of seasonal variation: a simulation study. Comput Methods Programs Biomed 2011;104:333-40
  2. Gamst J, Christiansen CF, Johansen MB, Rasmussen BS, Thomsen RW. Mortality among intensive care patients with pre-existing atrial fibrillation: a Danish cohort study. Intensive Care Medicine 2011;1;37(S1): S212
  3. Lip GY, Rasmussen LH, Olsson SB, Zetterstrand S, Stahre C, Bylock A et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy. Thromb Res 2011;127:91-9
  4. Rasmussen LH, Larsen TB, Due KM, Tjonneland A, Overvad K, Lip GY. Impact of vascular disease in predicting stroke, and death in patients with atrial fibrillation: The Danish Diet, Cancer and Health (DCH) study. J Thromb Haemost 2011;9:1301-7

2010

  1. Vibeke Høgh, Astrid Lauberg, Tina Højbjerg, Minna Holm Hansen & Birgitte Schantz Laursen. They should know me by now. Clinical Nursing no. 4- 2010 )
  2. Olsson SB, Rasmussen LH, Tveit A, Jensen E, Wessman P, Panfilov S et al. Safety and tolerability of an immediate-release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thromb Haemost 2010;103:604-12

 

Throughout the project a great number of abstracts and posters have been generated.  These are not disclosed on the homepage.

OPDATERET
4. januar 2018